Qiagen N.V.

WBAG:QGE2 Stock Report

Market Cap: €9.6b

Qiagen Valuation

Is QGE2 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of QGE2 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: QGE2 (€42.89) is trading below our estimate of fair value (€62.96)

Significantly Below Fair Value: QGE2 is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for QGE2?

Key metric: As QGE2 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for QGE2. This is calculated by dividing QGE2's market cap by their current earnings.
What is QGE2's PE Ratio?
PE Ratio107.6x
EarningsUS$92.93m
Market CapUS$10.00b

Price to Earnings Ratio vs Peers

How does QGE2's PE Ratio compare to its peers?

The above table shows the PE ratio for QGE2 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average43.9x
ERF Eurofins Scientific
28.5x18.4%€9.3b
CRL Charles River Laboratories International
23x12.2%US$9.5b
TECH Bio-Techne
77x21.1%US$11.6b
AVTR Avantor
47.1x36.2%US$14.6b
QGE2 Qiagen
107.6x34.4%€10.0b

Price-To-Earnings vs Peers: QGE2 is expensive based on its Price-To-Earnings Ratio (107.6x) compared to the peer average (43.9x).

Price to Earnings Ratio vs Industry

How does QGE2's PE Ratio compare vs other companies in the European Life Sciences Industry?

1 CompanyPrice / EarningsEstimated GrowthMarket Cap
QGE2 107.6xIndustry Avg. 37.3xNo. of Companies4PE020406080100+
1 CompanyEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: QGE2 is expensive based on its Price-To-Earnings Ratio (107.6x) compared to the European Life Sciences industry average (37.5x).

Price to Earnings Ratio vs Fair Ratio

What is QGE2's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

QGE2 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio107.6x
Fair PE Ration/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate QGE2's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst QGE2 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€42.89
€48.88
+14.0%
7.0%€57.21€42.91n/a17
Dec ’25€41.38
€48.00
+16.0%
8.0%€56.93€40.32n/a17
Nov ’25€39.71
€46.68
+17.5%
7.8%€55.41€40.46n/a17
Oct ’25€40.67
€46.17
+13.5%
7.8%€54.34€39.68n/a17
Sep ’25€41.44
€46.52
+12.3%
7.8%€54.76€39.99n/a17
Aug ’25€41.26
€46.80
+13.4%
8.4%€55.60€40.60n/a17
Jul ’25€37.90
€47.41
+25.1%
9.0%€57.80€40.94n/a17
Jun ’25€39.46
€46.55
+18.0%
9.3%€56.89€40.30n/a16
May ’25€38.98
€47.25
+21.2%
9.5%€57.85€39.75n/a16
Apr ’25€39.67
€47.66
+20.1%
8.9%€57.32€39.38n/a16
Mar ’25€39.91
€47.42
+18.8%
8.9%€57.03€39.19n/a16
Feb ’25€41.75
€47.71
+14.3%
9.3%€57.05€40.41n/a16
Jan ’25€40.51
€46.16
+14.0%
10.1%€56.35€39.45n/a17
Dec ’24€39.19
€45.79
+16.9%
10.6%€56.68€39.68€41.3816
Nov ’24€36.78
€48.03
+30.6%
11.8%€58.53€40.97€39.7115
Oct ’24€39.54
€51.00
+29.0%
8.8%€58.51€41.44€40.6715
Sep ’24€42.87
€49.98
+16.6%
10.2%€60.48€40.16€41.4414
Aug ’24€44.06
€49.74
+12.9%
10.4%€59.31€39.38€41.2614
Jul ’24€42.46
€51.18
+20.5%
10.4%€60.94€40.47€37.9014
Jun ’24€43.92
€51.92
+18.2%
10.3%€61.32€40.72€39.4613
May ’24€41.73
€52.45
+25.7%
8.1%€58.26€44.17€38.9811
Apr ’24€43.30
€53.45
+23.4%
10.4%€60.57€41.52€39.6712
Mar ’24€44.02
€52.46
+19.2%
10.2%€59.54€40.81€39.9112
Feb ’24€46.16
€51.31
+11.1%
9.7%€59.41€40.73€41.7512
Jan ’24€48.37
€54.44
+12.5%
9.2%€63.85€43.77€40.5111
Dec ’23€49.27
€54.44
+10.5%
9.2%€63.85€43.77€39.1911

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/27 02:14
End of Day Share Price 2024/12/27 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Qiagen N.V. is covered by 63 analysts. 20 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Daniel OwczarskiAvondale Partners
Catherine Ramsey SchulteBaird
Carla BänzigerBank Vontobel AG